Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
about
Emerging targeted therapies for glioma.Fms related tyrosine kinase 1 (Flt1) functions as an oncogene and regulates glioblastoma cell metastasis by regulating sonic hedgehog signaling.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses.Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages.The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.New Directions in Anti-Angiogenic Therapy for Glioblastoma.The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.Tumour-associated macrophages as treatment targets in oncology.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Angiogenesis inhibitors in tackling recurrent glioblastoma.Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Therapeutic targeting of the angiopoietin-TIE pathway.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Microenvironmental regulation of tumour angiogenesis.Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules.Integrating the glioblastoma microenvironment into engineered experimental models.Targeting Malignant Brain Tumors with Antibodies.The making of bispecific antibodiesRemodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles.Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Analysis of the vasculature by immunohistochemistry in paraffin-embedded brains.Advances in immunotherapeutic research for glioma therapy.Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.A cerebellar window for intravital imaging of normal and disease states in mice.Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.Endothelial Tie1-mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis.VEGF may contribute to macrophage recruitment and M2 polarization in the decidua.Improving immune-vascular crosstalk for cancer immunotherapy.Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.Macrophages: The Road Less Traveled, Changing Anticancer Therapy.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.
P2860
Q30241853-38CC632E-82F5-492F-A178-22AAACA4D45AQ33733026-EB4A5409-B3C8-44A6-8ACF-ED388EFC6701Q34548319-A367860B-6770-4CBF-95FE-F9FFEC87657CQ36831553-D524FFC8-8EBF-4832-8EAE-93154FCB4DE8Q37601508-A514FBCE-6AF4-4D00-A188-BB45A062685EQ38646337-1DAB8590-2AEB-49D1-89C9-811744178792Q38675589-48F86D4D-20B7-412B-BECB-7567E9F736E8Q38699394-C22710EC-46E5-4438-B197-17214AB92DB1Q38707904-8549BA24-AC2F-4CB6-B865-51DF5099DB64Q38736319-2371210D-56EB-40B4-9655-F7526153222DQ38861238-F8EF733C-6683-4D80-A866-83E761765D9CQ39022841-2964A935-1263-4DED-BC98-CFF39A047A39Q39022941-A3315CF4-C9DE-4BB3-843C-5ACCDC5AE6D9Q39034031-F2BEF1B1-5BE6-40EA-9DFF-884F2BEF5211Q39100693-32787E26-23A8-4976-821D-AC98870AAC2AQ39196377-3473241C-6429-4E90-8C80-5DA69FE92ACAQ39210287-35F29FB5-291E-4BC3-97C6-BCC2334469BAQ39259089-317DFE34-A88B-472E-81B0-E0B69A4704CFQ39267549-14C7D103-474D-4EA7-A962-7A91F9994F40Q39321127-30C3170D-541C-4C39-B04A-72D13FCFE671Q39403862-236D6CED-3ABF-43AD-8EA1-4893D62F9D30Q39433862-B70AD581-BE81-44E3-BAC1-ED20460DCF7FQ40283549-9E0780DD-67E7-433A-9B1A-EB63B03EAC43Q41609024-E39C0C1B-E8F6-4C1B-9958-5C0C1E25F535Q42267793-4EDBF272-A932-41AB-9303-C4C1148B680DQ42323236-F9E85919-8515-4367-9FAD-B6AD29911E0EQ46219895-1D175F3D-6FB8-4C61-84BD-79CF9C7EA56BQ47134647-BEEE2EFD-16E2-4C94-A0BD-56ED016B1292Q47221234-E70ACA4D-22EA-4B89-97D9-03934D798E94Q47272117-D16E2957-3B97-460C-AFB0-2A7102C1D3CEQ47569046-EE81431A-A738-4854-8D23-29296F7D2AA7Q47962563-146ACF19-376F-4B04-BB06-683CB817C7CEQ48032985-C09E1076-7428-412D-B77B-47B1114452B8Q48369496-C4496AE6-F9CE-442C-923F-68605414CB7CQ49884417-FAB80E54-A4B3-4F97-BBD5-E6B377EF5C1DQ50025011-32157B22-5269-4B87-A350-9DF95C8C0F64Q50051034-945AB6F5-59E9-4327-87A1-46911D7732C8Q50216662-86A7538C-6BD3-40F4-8AB0-7E7C525AF226Q52321369-333988B1-D475-4C3F-B768-457648B3E47FQ52590668-72F69852-6B85-4763-8379-4C8EB2A528A7
P2860
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ang-2/VEGF bispecific antibody ...... rolongs glioblastoma survival.
@en
type
label
Ang-2/VEGF bispecific antibody ...... rolongs glioblastoma survival.
@en
prefLabel
Ang-2/VEGF bispecific antibody ...... rolongs glioblastoma survival.
@en
P2093
P2860
P50
P356
P1476
Ang-2/VEGF bispecific antibody ...... rolongs glioblastoma survival.
@en
P2093
Alona Muzikansky
Ana Batista
Christine Lu-Emerson
Dai Fukumura
Dan G Duda
Hiroaki Wakimoto
Jennie W Taylor
Jonas Kloepper
Kay G Stubenrauch
Keehoon Jung
P2860
P304
P356
10.1073/PNAS.1525360113
P407
P577
2016-04-04T00:00:00Z